Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $7.00 price target on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 434.35% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. StockNews.com cut shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Robert W. Baird increased their price target on shares of Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.38.

Coherus BioSciences Stock Down 0.8 %

Coherus BioSciences stock opened at $1.31 on Thursday. The company has a fifty day simple moving average of $1.40 and a 200-day simple moving average of $1.27. The firm has a market capitalization of $150.93 million, a price-to-earnings ratio of -16.38 and a beta of 0.82. Coherus BioSciences has a 52-week low of $0.66 and a 52-week high of $2.87.

Institutional Trading of Coherus BioSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Systematic Financial Management LP purchased a new position in shares of Coherus BioSciences during the third quarter worth approximately $28,000. Steph & Co. purchased a new stake in shares of Coherus BioSciences during the 4th quarter worth $34,000. Hsbc Holdings PLC boosted its position in shares of Coherus BioSciences by 10.6% during the 2nd quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 9,905 shares in the last quarter. FMR LLC boosted its position in shares of Coherus BioSciences by 21.1% during the 3rd quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 39,204 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Coherus BioSciences by 19.5% during the 2nd quarter. Rhumbline Advisers now owns 154,904 shares of the biotechnology company’s stock worth $268,000 after buying an additional 25,241 shares during the last quarter. Institutional investors and hedge funds own 72.82% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.